A 'precision' type 1 immunotherapy stumbles: reading the DIAGNODE-3 interim
Diamyd’s Phase 3 interim analysis of its GAD-based antigen immunotherapy missed its primary target and did not meet the bar to continue as hoped.
Not every research story is good news, and the honest version matters just as much. On 27 March 2026, Diamyd reported that a planned early look at its large trial did not hit its main target: its immune therapy had not clearly slowed Type 1 at that point. The idea is a clever one, teaching the immune system to stop attacking insulin-making cells, but promising is not the same as proven.
- The therapy is a form of antigen-specific immunotherapy: it shows the immune system the very protein it wrongly attacks in Type 1, hoping to calm that attack.
- This was a Phase 3 trial, the large, late-stage kind that decides whether a treatment truly works, judged at a planned look partway through.
- It missed its primary endpoint at that point, meaning the main result it set out to prove did not clearly appear.
- A missed interim is a setback, not proof the whole approach is worthless, but it does mean this treatment is not close to your clinic.
The idea, and what stumbled
In Type 1, the immune system mistakes the body’s own insulin-making cells for a threat and destroys them. Antigen-specific immunotherapy tries to fix that at the source: show the immune system the exact protein it is reacting to, in a controlled way, and teach it to stand down. Diamyd’s version is built around a protein called GAD, and DIAGNODE-3 is the large Phase 3 trial testing it. At a planned interim analysis, a scheduled look at the data partway through, the treatment did not show a clear enough benefit on its main measure to clear the bar the researchers were hoping for. In trial language, it did not reach statistical significance on the primary endpoint at that timepoint.
A setback, not a verdict, and no hype
It would be wrong to wave this away, and equally wrong to treat it as the end of the road. Interim analyses are deliberately cautious, and the researchers will study the fuller picture, including whether the therapy helped particular groups of people. But it would also be wrong to pretend the field is on the edge of a breakthrough. Retraining the immune system in Type 1 has been attempted for years, and results like this are why prevention and cure remain unproven rather than available. If you have read a run of hopeful immunotherapy stories, this is the necessary other side of them: honest, unglamorous, and a reason to keep expectations on the ground.